OOIR: Observatory of International Research

Papers

(The H4-Index of EMBO Molecular Medicine is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019	232
YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis	221
Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID ‐19 patients	213
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology ar	204
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities	185
SARS ‐CoV‐2, bacterial co‐infections, and AMR : the deadly trio in COVID ‐19?	160
Sarcoma treatment in the era of molecular medicine	150
Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID‐19 pneumonia	131
Blood‐based biomarkers for Alzheimer's disease	127
SARS‐CoV‐2 outbreak investigation in a German meat processing plant	123
The rapidly evolving view of lysosomal storage diseases	121
COVID ‐19: lambda interferon against viral load and hyperinflammation	109
Mechanisms of small cell lung cancer metastasis	105
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?	103
Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19	100
Rationale for targeting complement in COVID‐19	99
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau	92
NAD ⁺ homeostasis in human health and disease	90
High‐resolution serum proteome trajectories in COVID‐19 reveal patient‐specific seroconversion	88
A Parkinson's disease Circ RNA s Resource reveals a link between circ SLC 8A1 and oxidative stress	83
Urinary proteome profiling for stratifying patients with familial Parkinson’s disease	83
Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection	81
Is BCG vaccination causally related to reduced COVID‐19 mortality?	81
Hydroxychloroquine in rheumatic autoimmune disorders and beyond	79
The ups and downs of caloric restriction and fasting: from molecular effects to clinical application	79

Innovations, challenges, and minimal information for standardization of humanized mice	79
Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice	75
Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity	74
Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation	71
Decreased serum level of sphingosine‐1‐phosphate: a novel predictor of clinical severity in COVID‐19	69
Fragmentation patterns and personalized sequencing of cell‐free DNA in urine and plasma of glioma patients	66
Emerging roles of ATG7 in human health and disease	65
Epithelial response to IFN‐γ promotes SARS‐CoV‐2 infection	63
A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2	60
Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer	60
Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders	60
Improvement of islet transplantation by the fusion of islet cells with functional blood vessels	58
Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers	57
Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers	55
Systemic inflammation after stroke: implications for post‐stroke comorbidities	54
Pharmacological reversal of synaptic and network pathology in human MECP2 ‐KO neurons and cortical organoids	54
Kaposiform lymphangiomatosis effectively treated with MEK inhibition	53
FAK activity in cancer‐associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer	53
SGK1 inhibition in glia ameliorates pathologies and symptoms in Parkinson disease animal models	52
Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis	51
The state of the art of bispecific antibodies for treating human malignancies	50
BAM15‐mediated mitochondrial uncoupling protects against obesity and improves glycemic control	50
Mitogen‐activated protein kinase activity drives cell trajectories in colorectal cancer	49
Reprogramming of profibrotic macrophages for treatment of bleomycin‐induced pulmonary fibrosis	49